Sandoz CEO Richard Saynor will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, detailing the company's strategy to seize what he calls an unprecedented "golden decade" opportunity in affordable medicines. The presentation, scheduled for January 13, 2026, at 18:45 CET, comes as reference medicines worth more than USD 600 billion are projected to lose exclusivity over the next ten years, creating significant potential for biosimilar and generic alternatives.
Saynor emphasized Sandoz's unique position as the only "pure-play" biosimilar and generic company, having delivered consistently on commitments since becoming a standalone entity in 2023. The company, which accounts for 80% of medicines used at just 30% of total healthcare costs according to its data, reported 2024 sales of USD 10 billion with strong double-digit growth in biosimilars. This financial momentum supports Sandoz's mid-term outlook of mid-single digit annual sales growth to 2028, with core EBITDA margin expansion forecasted to reach 24% to 26%.
The company's strategic progress includes breaking ground on a major new sterile biosimilars production center in Brnik, Slovenia, part of a multi-site project representing over USD 1.1 billion in investment. Sandoz also completed the acquisition of Just-Evotec Biologics' site and capabilities in Toulouse, France, and opened new penicillin production facilities as part of a USD 250 million investment in its vertically-integrated European antibiotic network. These developments complement six biosimilar launches in 2025, including three in the fourth quarter alone.
With 1,300 products supplied to over 100 countries and a pipeline of more than 400 assets, Sandoz targets approximately two-thirds of the USD 340 billion generic opportunity and 60% of the USD 322 billion biosimilar opportunity. The company's presentation slides, available after Saynor's presentation, detail its focused loss of exclusivity coverage strategy centered on oral solids and injectables, with longer-term attention on the emerging GLP-1 market.
A significant challenge remains what Sandoz calls the "biosimilar void," where more than 50 biologics facing loss of exclusivity in the next seven years currently have no biosimilar planned due to high clinical development costs. The company has led industry efforts toward regulatory streamlining of biosimilar development, which could substantially decrease both cost and time to market without compromising quality, safety, or efficacy.
Saynor concluded that Sandoz is poised to lead in making the next decade the "golden decade" of affordable healthcare, benefiting shareholders, customers, partners, and patients. The company's webcast of the presentation will be available for those interested in the detailed strategic outlook.
